Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Published Online
on December 8, 2003

Hypertension. 2003
Published online before print December 8, 2003, doi: 10.1161/01.HYP.0000107779.92645.89
A more recent version of this article appeared on February 1, 2004
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
43/2/243    most recent
01.HYP.0000107779.92645.89v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Han, J. H.
Right arrow Articles by Kim, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Han, J. H.
Right arrow Articles by Kim, S. H.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*CALCIUM COMPOUNDS
*CALCIUM, ELEMENTAL

Submitted on September 30, 2003
Revised on October 15, 2003

Attenuation of Lysophosphatidylcholine-Induced Suppression of ANP Release From Hypertrophied Atria

Jeong Hee Han; Chunhua Cao; Su Mi Kim; Feng Lian Piao; and Suhn Hee Kim*

From the Department of Physiology, Medical School, Institute for Medical Sciences, Chonbuk National University, Jeonju, Korea.

* To whom correspondence should be addressed. E-mail: shkim{at}moak.chonbuk.ac.kr.

Abstract--Lysophosphatidylcholine (LPC) is an endogenous phospholipid released from the cell membrane during ischemia, and it has potent cardiac effects, including inhibition of atrial natriuretic peptide (ANP) release. The aim of this study was to investigate the effects of LPC on hemodynamics and ANP release in hypertrophied atria and to define its mechanism. Isolated, perfused, beating, hypertrophied atria from monocrotaline-treated rats were used. LPC (30 µmol/L), a mixture of stearoyl-LPC, palmitoyl-LPC, and oleoyl-LPC, caused suppression of ANP release, which was markedly attenuated in hypertrophied atria compared with nonhypertrophied atria. Suppression of ANP release by stearoyl-LPC, palmitoyl-LPC, or oleoyl-LPC was also attenuated in hypertrophied atria. The potency appeared to be dependent on the species of fatty acid residue of LPC. Changes in ANP release by LPC, palmitoyl-LPC, and oleoyl-LPC were positively correlated with the degree of cardiac hypertrophy, but that by stearoyl-LPC was not. Changes in ANP release by LPC also were negatively correlated with changes in pulse pressure. Stearoyl-LPC caused an increase in intracellular Ca2+ in single, atrial myocytes in a concentration-dependent manner, which was markedly attenuated in hypertrophied atrial myocytes. These results suggest that attenuation of LPC-induced suppression of ANP release from hypertrophied atria might partly be related to changes in pulse pressure in terms of cardiac hypertrophy and/or disturbance of intracellular Ca2+ regulation.


Key words: calcium • hypertrophy • natriuretic peptides • hypertension




This article has been cited by other articles:


Home page
HypertensionHome page
A. M. Richards
Natriuretic Peptides: Update on Peptide Release, Bioactivity, and Clinical Use
Hypertension, July 1, 2007; 50(1): 25 - 30.
[Full Text] [PDF]